TrialClinIQ | $150,000 | (Apr 29, 2026)
Lighthouse Pharmaceuticals | $12,000,000 | (Apr 29, 2026)
Windmill(US) | $12,000,000 | (Apr 29, 2026)
Restate
- 13/06/2024
- Seed
- $7,000,000
Building modern applications is inherently hard because they are often distributed, need to be scalable as well as consistent and are ideally highly-available. Fulfilling these non-functional requirements often entails high development costs. Restate frees you from these problems by offering a framework to easily build resilient applications using distributed durable async/await.
- Industry Software Development
- Website https://restate.dev/
- LinkedIn https://www.linkedin.com/company/restatedev/
Related People
Stephan EwenFounder
Germany -
Berlin, Berlin
Founder at Restate (https://restate.dev/), working on a new way of building distributed applications that is faster, more scalable, and more resilient. Restate lets you build applications with *durable async/await*, powered by a sophisticated event-driven system underneath.
Previously, I was one of the main creators of Apache Flink (https://flink.apache.org/). I also co-founded dataArtisans, which was acquired by Alibaba and rebranded to Ververica
IC Realtime | $2,000,000 | (Apr 29, 2026)
Golden Child | $37,000,000 | (Apr 29, 2026)
Hypervision Surgical | $22,962,410 | (Apr 29, 2026)
dehaze | $3,746,192 | (Apr 29, 2026)
Clarasight | $11,500,000 | (Apr 29, 2026)
Liquid Instruments | $50,000,000 | (Apr 29, 2026)
TriFetch | $1,900,000 | (Apr 28, 2026)
Linexa | $2,342,840 | (Apr 28, 2026)
HrFlow.ai | $7,000,000 | (Apr 28, 2026)